|
1.
|
|
11 p, 379.4 KB |
Postoperative Chemotherapy Use and Outcomes From ADAURA : Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
/
Wu, Yi-Long (Guangdong Lung Cancer Institute) ;
John, Thomas (Austin Health) ;
Grohe, Christian (Evangelische Lungenklinik) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Goldman, Jonathan W. (University of California) ;
Kim, Sang-We (University of Ulsan) ;
Kato, Terufumi (Kanagawa Cancer Center) ;
Laktionov, Konstantin (Blokhin National Medical Research Center of Oncology) ;
Vu, Huu Vinh (Choray Hospital) ;
Wang, Zhije (Chinese Academy of Medical Sciences) ;
Lu, Shun (Shanghai Jiao Tong University) ;
Lee, Kye Young (Konkuk University Medical Center) ;
Akewanlop, Charuwan (Siriraj Hospital) ;
Yu, Chong-Jen (National Taiwan University College of Medicine) ;
de Marinis, Filippo (European Institute of Oncology) ;
Bonanno, Laura (Istituto Oncologico Veneto) ;
Domine, Manuel (Instituto de Investigación Sanitaria-Fundación Jiménez Díaz) ;
Shepherd, Frances A. (University of Toronto) ;
Zeng, Lingmin (AstraZeneca) ;
Atasoy, Ajlan (AstraZeneca) ;
Herbst, Roy S. (Yale School of Medicine) ;
Tsuboi, Masahiro (National Cancer Center Hospital East) ;
Universitat Autònoma de Barcelona
Introduction: Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found to have a clinically meaningful improvement in disease-free survival (DFS) in patients with resected stages IB to IIIA EGFR-mutated (EGFRm) NSCLC. [...]
2022 -  10.1016/j.jtho.2021.10.014
Journal of Thoracic Oncology, Vol. 17 Núm. 3 (march 2022) , p. 423-433
|
|
|
2.
|
|
14 p, 563.4 KB |
Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors : The necessity of repeated molecular analysis
/
González-Larriba, José Luis (Hospital Universitario Clínico San Carlos (Madrid)) ;
Lázaro-Quintela, Martín (Complexo Hospitalario Universitario de Vigo) ;
Cobo, Manuel (Hospital Regional Universitario de Málaga) ;
Dómine, Manuel (Hospital Universitario Fundación Jiménez Díaz) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ;
Universitat Autònoma de Barcelona
One of the most important advances in the treatment of non-small cell lung cancer (NSCLC) has been the identification of molecular alterations vulnerable to targeted inhibition, such as mutations in the epidermal growth factor receptor (EGFR) gene. [...]
2017 - 10.21037/tlcr.2017.10.03
Translational Lung Cancer Research, Vol. 6 (january 2017) , p. S21-S34
|
|
|
3.
|
|
9 p, 902.3 KB |
Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients : an exploratory longitudinal study
/
Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Garcia-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Gonzalez-Larriba, José Luis (Hospital Clínico San Carlos (Madrid)) ;
Coves, Juan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
De-Castro, Javier (Hospital Universitario La Paz (Madrid)) ;
Domine, Manuel (Hospital Universitario Fundación Jiménez Díaz) ;
Lianes, Piar (Hospital de Mataró. Consorci Sanitari del Maresme) ;
Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ;
Remon, Jordi (CIOCC Barcelona - HM Delfos) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
Garrido, Pilar (Hospital Universitario Ramón y Cajal (Madrid)) ;
Universitat Autònoma de Barcelona
Little is known about the impact of sex on lung cancer patients from the psychological, economic and social perspectives. This study was designed to explore the psychosocial and economic impact according to sex of metastatic non-small cell lung cancer (mNSCLC) in patients and caregivers. [...]
2020 - 10.1186/s40359-020-00489-z
BMC Psychology, Vol. 8 Núm. 1 (december 2020) , p. 123
|
|
|
4.
|
|
6 p, 380.2 KB |
Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer : final results of a randomised phase 2 clinical trial
/
Gridelli, C. (S.G. Moscati Hospital) ;
Ciuleanu, Tudor Eliade (Institutui. Oncologic I. Chircuta) ;
Domine, M. (Fundacion Jimenez Diaz) ;
Szczesna, A. (Mazowieckie Centrum) ;
Bover, I. (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Cobo, M. (Instituto de Investigaciones Biomédicas (IBIMA)) ;
Kentepozidis, N. (251 General Airforce Hospital) ;
Zarogoulidis, K. (Papanikolaou General Hospital) ;
Kalofonos, C. (University Hospital of Patras) ;
Kazarnowisz, A. (Oddzial Onkologiiz Pododdziatem) ;
Korozan, M. (Hospicjum Dutkiewicza SAC) ;
de las Peñas, R (Hospital Provincial de Castellon) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Chella, A. (A.O.U. di Pisa Hospital) ;
Griesinger, F. (Pius Hospital) ;
Bournakis, E. (University Hospital "Aretaieion") ;
Sadjadian, P. (Johannes Wesling Klinikum) ;
Kotsakis, A. (University General Hospital of Larissa) ;
Chinet, T. (Hopital Ambroise Paré) ;
Syrigos, K.N. (General Hospital of Thoracic Diseases "Sotiria") ;
Correale, P. (University Hospital of Siena) ;
Gallou, C. (Vaxon-Biotech) ;
Jamet, J.M. (Vaxon-Biotech) ;
Vetsika, E.K. (University General Hospital of Heraklion) ;
Kosmatopoulos, K. (Vaxon-Biotech) ;
Georgoulias, V. (University General Hospital of Heraklion) ;
Universitat Autònoma de Barcelona
The cancer vaccine Vx-001, which targets the universal tumour antigen TElomerase Reverse Transcriptase (TERT), can mount specific Vx-001/TERT CD8 + cytotoxic T cells; this immune response is associated with improved overall survival (OS) in patients with advanced/metastatic non-small cell lung cancer (NSCLC). [...]
2020 - 10.1038/s41416-020-0785-y
British Journal of Cancer, Vol. 122 Núm. 10 (december 2020) , p. 1461-1466
|
|
|
5.
|
|
11 p, 824.1 KB |
SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)
/
Dómine Gómez, Manuel (Hospital Universitario Fundación Jiménez Díaz) ;
Moran, T. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Martí, J.L. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ;
Provencio, M. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Olmedo, M.E. (Hospital Universitario Ramón y Cajal (Madrid)) ;
Ponce, S. (Hospital 12 de Octubre (Madrid)) ;
Blasco, A. (Consorcio Hospital General Universitario de Valencia. CIBERONC) ;
Cobo, M. (Hospital Regional Universitario de Málaga (Carlos Haya)) ;
Universitat Autònoma de Barcelona
Small-cell lung cancer (SCLC) accounts for 15% of lung cancers. Only one-third of patients are diagnosed at limited stage. The median survival remains to be around 15-20 months without significative changes in the strategies of treatment for many years. [...]
2020 - 10.1007/s12094-020-02295-w
Clinical & Translational Oncology, Vol. 22 Núm. 2 (january 2020) , p. 245-255
|
|
|
6.
|
|
11 p, 421.8 KB |
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
/
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Goldman, Jonathan W. (David Geffen School of Medicine. University of California Los Angeles) ;
John, Thomas (Department of Medical Oncology. Austin Health) ;
Grohe, Christian (Klinik fur € Pneumologie-Evangelische Lungenklinik Berlin Buch) ;
Laktionov, Konstantin (N.N. Blokhin National Medical Research Center of Oncology (Rússia)) ;
Kim, Sang-We (Department of Oncology. Asan Medical Center) ;
Kato, Terufumi (Depart-ment of Thoracic Oncology. Kanagawa Cancer Center) ;
Vu, Huu Vinh (Department of Thoracic Surgery. Choray Hospital) ;
Lu, Shun (Lung Cancer Center. Shanghai Chest Hospital. Shanghai Jiao Tong University) ;
Li, Shanqing (Department of Thoracic Surgery. Peking Union Medical College Hospital. Chinese Academy of Medical Sciences) ;
Lee, Kye Young (Pre-cision Medicine Lung Cancer Center. Konkuk University Medical Center) ;
Akewanlop, Charuwan (Division of Medical Oncology. Faculty of Medicine. Siriraj Hospital) ;
Yu, Chong-Jen (Department of Internal Medicine. National Taiwan University Hospital Hsinchu Branch. National Taiwan University College of Medicine) ;
De Marinis, Filippo (Thoracic Oncology Division. European Institute of Oncology (IEO). IRCCS) ;
Bonanno, Laura (Medical Oncology 2. Istituto Oncologico Veneto (IOV). IRCCS) ;
Domine, Manuel (Hospital Universitario Fundacion Jimenez Díaz. Servicio de Oncología) ;
Shepherd, Frances A. (Department of Medical Oncology and Hematology. University Health Network. Princess Margaret Cancer Center. the University of Toronto) ;
Atagi, Shinji (Department of Thoracic Oncology. National Hospital Organization Kinki-Chuo Chest Medical Center) ;
Zeng, Lingmin (Late Oncology Statistics. AstraZeneca) ;
Kulkarni, Dakshayini (Late Oncology R&D. AstraZeneca) ;
Medic, Nenad (AstraZeneca Oncology Business Unit. Academy House) ;
Tsuboi, Masahiro (Department of Thoracic Surgery and Oncology. National Cancer Center Hospital East) ;
Herbst, Roy S. (Medical Oncology. Yale School of Medicine. Yale Cancer Center) ;
Wu, Yi-Long (Guangdong Lung Cancer Institute)
Purpose: In the phase III ADAURA trial, adjuvant treatment with osimertinib versus placebo, with/without prior adjuvant chemotherapy, resulted in a statistically significant and clinically meaningful disease-free survival benefit in completely resected stage IB-IIIA EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). [...]
2022 - 10.1158/1078-0432.CCR-21-3530
Clinical Cancer Research, Vol. 28 Núm. 11 (january 2022) , p. 2286-2296
|
|
|
7.
|
|
14 p, 4.8 MB |
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
/
Casarrubios, Marta (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Provencio, Mariano (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Nadal, Ernest (Institut d'Investigació Biomèdica de Bellvitge) ;
Insa, Amelia (Hospital Clínic Universitari (València)) ;
Del Rosario García-Campelo, María (Complejo Hospitalario Universitario de A Coruña) ;
Lázaro, Martín (Hospital Universitario de Vigo) ;
Dómine, Manuel (Hospital Universitario Fundación Jiménez Díaz) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Rodríguez-Abreu, Delvys (Hospital Universitario Insular de Gran Canaria) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia) ;
de Castro, Javier (Hospital Universitario La Paz (Madrid)) ;
Cobo, Manuel (Instituto de Investigación Biomédica de Málaga) ;
López-Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Del Barco Morillo, Edel (Hospital Universitario de Salamanca) ;
Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Barneto Aranda, Isidoro (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Sierra-Rodero, Belén (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Martinez-Toledo, Cristina (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Fernández-Miranda, Ismael (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Serna-Blanco, Roberto (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Romero, Atocha (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Calvo, Virginia (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Cruz-Bermúdez, Alberto (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana)
Background Neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC) has improved pathological responses and survival rates compared with chemotherapy alone, leading to Food and Drug Administration (FDA) approval of nivolumab plus chemotherapy for resectable stage IB-IIIA NSCLC (AJCC 7th edition) without ALK or EGFR alterations. [...]
2022 - 10.1136/jitc-2022-005320
Journal for immunotherapy of cancer, Vol. 10 Núm. 9 (september 2022) , p. e005320
|
|
|
8.
|
|
18 p, 1.7 MB |
Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma : A Systematic Review and Meta-Analysis
/
Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya)) ;
González-Cao, María (Hospital Dexeus) ;
Domine, Manuel (Hospital Universitario Fundación Jiménez Díaz) ;
de Castro, Javier (Hospital Universitario La Paz (Madrid)) ;
Cobo, Manuel (Instituto de Investigación Biomédica de Málaga) ;
Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Navarro, Alejandro (Vall d'Hebron Institut d'Oncologia) ;
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ;
Trigo, José Manuel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Mosquera, Joaquín (Complejo Hospitalario Universitario de A Coruña) ;
Crama, Leonardo (Medical Department Roche) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza)
Introduction: The addition of immune checkpoint inhibitors (ICIs) to conventional chemotherapy (CT) as first-line treatment improves survival in extensive-stage small-cell lung cancer (ES-SCLC). The aim of this meta-analysis was to determine the relative efficacy of first-line ICIs compared with CT in patients with ES-SCLC. [...]
2022 - 10.1007/s40487-021-00182-0
Oncology and Therapy, Vol. 10 Núm. 1 (june 2022) , p. 167-184
|
|
|
9.
|
|
13 p, 2.9 MB |
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
/
Sierra-Rodero, Belén (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Cruz-Bermúdez, Alberto (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Nadal, Ernest (Institut d'Investigació Biomèdica de Bellvitge) ;
Garitaonaindiá, Yago (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Insa, Amelia (INCLIVA. Valencia) ;
Mosquera, Joaquín (Complejo Hospitalario Universitario de A Coruña) ;
Casal-Rubio, Joaquín (Hospital Universitario de Vigo) ;
Dómine, Manuel (Hospital Universitario Fundación Jiménez Díaz) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Rodríguez-Abreu, Delvys (Hospital Universitario Insular de Gran Canaria) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia) ;
de Castro, Javier (Hospital Universitario La Paz (Madrid)) ;
Cobo, Manuel (Hospital Regional Universitario de Málaga) ;
López Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Del Barco Morillo, Edel (Hospital Universitario de Salamanca) ;
Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Barneto Aranda, Isidoro (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Viteri, Santiago (Instituto Oncológico Dr. Rosell. Hospital Universitario Quiron Dexeus) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Laza-Briviesca, Raquel (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Casarrubios, Marta (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Garciá-Grande, Aránzazu (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Romero, Atocha (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Franco, Fernando (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Provencio, Mariano (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana)
Background Pneumonitis (Pn) is one of the main immune-related adverse effects, having a special importance in lung cancer, since they share affected tissue. Despite its clinical relevance, Pn development remains an unpredictable treatment adverse effect, whose mechanisms are mainly unknown, being even more obscure when it is associated to chemoimmunotherapy. [...]
2021 - 10.1136/jitc-2021-002804
Journal for immunotherapy of cancer, Vol. 9 Núm. 8 (august 2021) , p. e002804
|
|
|
10.
|
|
9 p, 1.3 MB |
A plain language summary of results from the ADAURA study : osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer
/
Wu, Yi-Long (Guangdong Lung Cancer Institute. Guangdong Provincial People's Hospital. Guangdong Academy of Medical Sciences) ;
Tsuboi, M. (Department of Thoracic Surgery and Oncology. National Cancer Center Hospital East) ;
John, T. (Department of Medical Oncology. Austin Health) ;
Grohe, C. (Department of Respiratory Diseases. Evangelische Lungenklinik) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Goldman, J.W. (David Geffen School of Medicine. University of California) ;
Laktionov, K. (Center of Innovative Technologies and Oncology. N.N. Blokhin Russian Cancer Center. Russian Academy of Medical Sciences) ;
Kim, S.W. (Department of Oncology. Asan Medical Center. University of Ulsan. College of Medicine) ;
Kato, T. (Department of Thoracic Oncology. Kanagawa Cancer Center) ;
Vu, H.V. (Department of Thoracic Surgery. Choray Hospital) ;
Lu, S. (Lung Cancer Center. Shanghai Chest Hospital. Shanghai Jiao Tong University) ;
Lee, K.Y. (Precision Medicine. Lung Cancer Center. Konkuk University. Medical Center) ;
Akewanlop, C. (Division of Medical Oncology. Faculty of Medicine. Siriraj Hospital) ;
Yu, C.J. (Department of Internal Medicine. National Taiwan University. Hospital Hsinchu Branch. National Taiwan University. College of Medicine) ;
De Marinis, Filippo (Thoracic Oncology Division. European Institute of Oncology (IEO). IRCCS) ;
Bonanno, Laura (Medical Oncology 2. Istituto Oncologico Veneto IOV IRCCS) ;
Dómine Gómez, Manuel (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Shepherd, F.A. (Department of Medical Oncology and Hematology. University Health Network. Princess Margaret Hospital. University of Toronto) ;
Zeng, L. (Late Oncology Statistics. AstraZeneca) ;
Hodge, R. (Late Oncology Statistics. AstraZeneca) ;
Atasoy, A. (Late Oncology Research and Development. AstraZeneca) ;
Rukazenkov, Y. (Late Oncology Research and Development. AstraZeneca) ;
Herbst, Roy S (Medical Oncology. Yale School of Medicine. Yale Cancer Center)
Here, we summarize the initial results from the ADAURA clinical study looking at treatment with osimertinib in patients with a specific type of non-small cell lung cancer (also called NSCLC). Osimertinib (TAGRISSO®) is a medication used to treat a type of NSCLC with a change (mutation) in the EGFR gene, known as EGFR-mutated NSCLC. [...]
2021 - 10.2217/fon-2021-0752
Future oncology (London, England), Vol. 17 Núm. 35 (december 2021) , p. 4827-4835
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
